



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of : Valerie AUTIER et al.

Serial No.: 10/541,377

Group Art Unit: 1614

Filed: July 6, 2005

Examiner: ZHANG, Nancy L.

Title: KYNURENINE 3-HYDROXYLASE INHIBITORS FOR THE TREATMENT OF DIABETES

**REPLY**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450


SIR:

In response to the Office Action mailed on December 21, 2006, applicants elect with traverse Group II, claims 1-21 and 27-28. As a species applicants elect with traverse the ninth compound of original claim 16, which compound is also disclosed on pages 30 and 43 of the specification, i.e., 2-(2'-naphthylthio)-4-phenyl-4-oxobutanoic acid. The traversal is on the grounds that the patent office has not established that it would pose an undue burden to examine the full scope of the claimed invention.

Additionally, applicants bring the attention of the Examiner to MPEP § 821.04, Rejoinder, which states that "if the elected invention is directed to the product and the claims directed to the product are subsequently found patentable, process claims [both process of making and using] which either depend from or include all the limitations of the allowable product will be rejoined." If the restriction requirement is maintained at this point, rejoinder of the non-elected claims is respectfully requested at the proper time in accord with the rejoinder provisions of the MPEP.

The Commissioner is hereby authorized to charge any fees associated with this response or credit any overpayment to Deposit Account No. 13-3402.

Respectfully submitted,

  
Csaba Henter, Reg. No. 50,908  
Anthony J. Zelano, Reg. No. 27,969  
Attorneys for Applicants

MILLEN, WHITE, ZELANO & BRANIGAN, P.C.  
Arlington Courthouse Plaza I  
2200 Clarendon Boulevard, Suite 1400  
Arlington, Virginia 22201  
Direct Dial: 703-812-5331  
Facsimile: 703-243-6410

Attny. Docket No.: Merck-3028

Filed: **January 22, 2007**

K:\MERCK\3000 - 3999\3028\RESTR REPLY JAN 07.DOC